Clinical trials: Open Label
Aspergillosis
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
- Trial name
- NCT00047827
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Astellas Pharma Inc
Protein Losing Enteropathy
Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
Protein Losing Enteropathy (PLE) is a serious medical condition that may develop in children and adults with congenital heart disease for which a palliative procedure known as the "Fontan procedure" has been performed.
- Trial name
- NCT01161641
- Testing
- ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
Influenza
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
The main purpose of this study is to learn if influenza vaccines (live attenuated and inactivated influenza vaccines), when given to school-aged children 4 to 18 years of age, can stop or lessen the influenza (flu) outbreak in…
- Trial name
- CEI (NCT00138294)
- Testing
- live attenuated and inactivated influenza vaccines
- Where
- 2 sites in United States
- Volunteers
- 29,255 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Meningitis, Meningococcal Infection
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
- Trial name
- NCT00806195
- Testing
- MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine
- Where
- 153 sites in United States, China and 4 more
- Volunteers
- 7,744 people, healthy volunteers welcome
- Sponsor
- Novartis
Leukemia, Lymphoblastic, Acute, Pediatric
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Trial name
- NCT00042341
- Testing
- clofarabine (IV formulation)
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
HIV Infections
A Study of L-735,524 in HIV-Positive Children and Adolescents
To evaluate the safety, tolerability, and plasma concentration profiles of indinavir sulfate ( MK-639; Crixivan ) in HIV-seropositive older children and adolescents.
- Trial name
- NCT00002351
- Testing
- Indinavir sulfate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Pediatrics
SPOG 2015 FN Definition. A Multi-center Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia
In a multi-center open-label cluster-randomized controlled parallel-group multiple crossover non-inferiority trial in children and adolescents up to 20 years diagnosed with cancer requiring chemotherapy, primarily the safety, and…
- Conditions
- Cancer, Pediatrics, Fever, Neutropenia
- Trial name
- NCT02324231
- Testing
- 39.0°C temperature limit defining fever, 38.5°C temperature limit defining fever
- Where
- 6 sites in Switzerland
- Volunteers
- 269 people
- Sponsor
- Swiss Pediatric Oncology Group
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
This is a FIH, single center, open label, non-randomized, single-arm, Phase I clinical trial to evaluate the safety and tolerability of CD5 CAR T (CT125B) cells in subjects with relapsed or refractory T-cell acute lymphoblastic…
- Trial name
- NCT05487495
- Testing
- CD5 CAR T (CT125B)
- Where
- China
- Sponsor
- Beijing Boren Hospital
Oculopharyngeal Muscular Dystrophy
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia
Subjects who have enrolled in the oculopharyngeal muscular dystrophy (OPMD) natural history study (Study BNTC-OPMD-NH-001) and have completed at least 6 months of follow up in Study BNTC-OPMD-NH-001 may be eligible to participate…
- Trial name
- NCT06185673
- Testing
- BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2, BB-301: Dose escalation phase 1b cohort 3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benitec Biopharma, Inc.
Pompe Disease (Late-onset)
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric…
- Trial name
- NCT03911505
- Testing
- Cipaglucosidase Alfa, Miglustat
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 21 people
- Sponsor
- Amicus Therapeutics
Cerebral Palsy, Neurological Conditions
Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
This is an open-label clinical research study of an oral glycopyrrolate liquid for the treatment of chronic moderate to severe drooling in patients with cerebral palsy or other neurological conditions.
- Conditions
- Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
- Trial name
- NCT00491894
- Testing
- Oral Glycopyrrolate Liquid
- Where
- 7 sites in United States
- Volunteers
- 137 people
- Sponsor
- Shionogi
Autism Spectrum Disorder (ASD)
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.
- Trial name
- NCT03715153
- Testing
- BUMETANIDE (S95008) for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 211 people
- Sponsor
- Institut de Recherches Internationales Servier
Hereditary Angioedema
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
The main aim of the study is to check for side effects from icatibant in children and teenagers with hereditary angioedema (HAE).
- Trial name
- NCT04654351
- Testing
- TAK-667
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Takeda
Uncomplicated Plasmodium Falciparum Malaria
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs…
- Trial name
- FD-TACT (NCT05951595)
- Testing
- Artemether-Lumefantrine-Amodiaquine (ALAQ), Artemether-Lumefantrine (AL), Artesunate-Amodiaquine (ASAQ)
- Where
- Rwanda
- Volunteers
- 1,680 people
- Sponsor
- University of Oxford
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis
Parkinson's Disease
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations.
- Trial name
- NCT00936676
- Testing
- rasagiline mesylate
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 684 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Healthcare Associated Infection
Monitors to Improve Indoor Carbon Dioxide (CO2) Concentrations in the Hospital
Ventilation with fresh outdoor air has recently gained considerable attention as a means to reduce the potential risk of indoor aerosol transmission of respiratory pathogens such as severe acute respiratory syndrome coronavirus 2…
- Trial name
- MICH (NCT04770597)
- Testing
- Aranet4 Home CO2 monitor
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Imelda Hospital, Bonheiden
Mucopolysaccharidosis III-B
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.
- Trial name
- NCT06488924
- Testing
- JR-446
- Where
- 4 sites in Japan
- Volunteers
- 10 people
- Sponsor
- JCR Pharmaceuticals Co., Ltd.
Hydronephrosis, Neurogenic Bladder
Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
Primary objective was to determine efficacy of Alfuzosin in the treatment of children and adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to elevated detrusor Leak Point Pressure [LPP] of…
- Trial name
- Alfahydro (NCT00576823)
- Testing
- Alfuzosin
- Where
- 12 sites in Bulgaria, Canada and 10 more
- Volunteers
- 25 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.